295 results on '"Bak, Martin"'
Search Results
2. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model
3. Deciphering the monocyte-targeting mechanisms of PEGylated cationic liposomes by investigating the biomolecular corona
4. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
5. Mechanisms of selective monocyte targeting by liposomes functionalized with a cationic, arginine-rich lipopeptide
6. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
7. Ensemble‐based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long‐term risk of metastases.
8. Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
9. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
10. Modulating the antibody density changes the uptake and transport at the blood-brain barrier of both transferrin receptor-targeted gold nanoparticles and liposomal cargo
11. Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
12. Supplementary Table S3 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
13. Supplementary Figures Legends from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
14. Supplementary Figure S2 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
15. CarboCell combinatorial immunotherapy orchestrates curative anticancer immune activation of the tumor microenvironment
16. 1169 Systemic administration of TLR7/8 agonist micelles triggers a potent anti-tumor response mediated by neutrophils as primary effector cells followed by establishment of an immune memory response
17. Enhancing Adoptive Cell Therapy by T Cell Loading of SHP2 Inhibitor Nanocrystals before Infusion
18. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer
19. Systemic TLR7/8 micelles trigger a novel and potent anti-tumor response by strong recruitment of neutrophils leading to massive tumor cell killing.
20. The Role of Growth Hormone, Insulin-Like Growth Factors, Epidermal Growth Factor and Transforming Growth Factor β in Diabetic Kidney Disease: An Update
21. The Role of Growth Factors in Diabetic Kidney Disease
22. 771 Novel lipid nanoparticle vaccine platform for efficient delivery of high- and low-affinity epitopes
23. 611 Exploiting T cells as vehicles of liposomal SHP2i to enhance adoptive cell therapy
24. Publisher Correction:Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)
25. Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer
26. The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer
27. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype
28. Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast Cancer
29. Novel lipid nanoparticle vaccine platform for efficient delivery of high- and low-affinity epitopes
30. Morbidity as a predictor for participation in the Danish national mammography screening program:A cross-sectional study
31. Morbidity as a Predictor for Participation in the Danish National Mammography Screening Program: A Cross-Sectional Study
32. Abstract B66: Deep TLR PrimedTM T cells induce potent antitumor activity without systemic toxicity
33. Quality assurance of fine needle aspiration cytology (FNAC) in breast cancer screening: F1.4
34. Effects of the adenosine A1 receptor inhibitor FK 838 on proximal tubular fluid output in rats
35. A Model for Intracortical Visual Prosthesis Research
36. Mammography screening in the county of Fyn November 1993–December 1999
37. Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats
38. The Role of Growth Factors in Diabetic Kidney Disease
39. Additional file 1: of Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer
40. Additional file 2: of Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer
41. Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer
42. CYPOR is a novel and independent prognostic biomarker of recurrence‐free survival in triple‐negative breast cancer patients
43. Measurement of renal vein blood flow in rats by high-field magnetic resonance
44. Cytobrush and endocervical curettage in the diagnosis of dysplasia and malignancy of the uterine cervix
45. Additional file 3: Table S3. of Outcome of breast cancer screening in Denmark
46. Additional file 1: Table S1. of Outcome of breast cancer screening in Denmark
47. Additional file 5: Table S5. of Outcome of breast cancer screening in Denmark
48. Additional file 4: Table S4. of Outcome of breast cancer screening in Denmark
49. Additional file 2: Table S2. of Outcome of breast cancer screening in Denmark
50. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.